National and Kapodistrian University of Athens
Μηχανισμός ανάπτυξης και θεραπευτική αντιμετώπιση της χοριοειδικής νεοαγγείωσης της ωχράς κηλίδας σε ασθενείς με παθολογικό υπόστρωμα: αγγειοειδείς ταινίες
Abstract
dc:descriptionIntroduction: Macular choroidal neovascularization (CNV) is the most serious complication of Angioid streaks (AS). It has a poor natural course usually resulting in central visual loss. Treatment of CNV in patients with AS with laser photocoagulation, photodynamic therapy and submacular surgery were not effective. Intravitreal injections of vascular endothelial growth factor (anti-VEGF) drugs is currently the most effective treatment. However, published case series report on the final effect of anti-VEGF therapy on the best corrected visual acuity (BCVA). No one study has compared the functional outcomes, i.e., BCVA, by the end of the first and second year of therapy. Purpose: The aim of our study was to compare 12 and 24-month results of intravitreal ranibizumab therapy in the management of choroidal neovascularization (CNV) secondary to angioid steaks (ST). This could be of clinical importance helping us planning optimal dosing strategies. Design: 24-month prospective, open-label, interventional clinical study. Methods: Over a 7-year period, a consecutive series of treatment-naive eyes with macular CNV due to AS were treated with intravitreal ranibizumab (0.5 mg). The main outcome measure was changes in best-corrected visual acuity (BCVA) at 12 and 24 months as compared to baseline. Results: Twenty eyes completed 24-month therapy and regular follow up. Each eye received a median of 7 (7-10) and 2 (1-5) injections during the first and the second year, respectively. BCVA was improved at 12 (0.42±0.26 logMAR) and 24 months (0.44±0.22 logMAR) as compared to baseline (0.75±0.26 logMAR) (p<0.001), but did not change between the 12 and 24-month follow up (p=0.48). BCVA was improved in 15 (75%) and 16 (80%) of the eyes, but in 4 (20%) and 3 (15%) remain unchanged (p=0.92) at 12 and 24 months, respectively. Central retinal thickness was reduced at 12 (287±87 μm) and 24 months (322±98 μm) as compared to baseline (382±96 μm) (p<0.001), but did not change between the 12 and 24-month (p=0.14). No injection or drug-related side-effects were observed. Conclusion: Our 24-month prospective study have clearly shown that intravitreal injections of ranibizumab in patients with macular CNV secondary to AS improves visual acuity during the first year and stabilizes it during the second year of therapy. We can postulate that it is mostly the treatment during the first year that leads to functional and anatomical improvement while, during the second year, treatment mainly preserves the first-year results.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ladas, Dimitrios
- Λαδάς, Δημήτριος
Subjects
dc:subject × 15Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42426